News

H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial
On May 27, analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) ...
Clinical Trials Arena on MSN12h
Enrolment completed in Huonslab’s Phase I trial of HLB3-002
By the latter half of this year, the company aims to submit a biologics license application to Korean authorities.
scmp.com1d
PANDA LEGEND (H002) 熊噹噹
16.1 38.5 1.02.2 (23.7) - ST / 1050 m / aw / 5 bt 9 / H Bentley ...